Poonkuzhali, B. ; Srivastava, A. ; Quernin, M. H. ; Dennison, D. ; Aigrain, E. J. ; Kanagasabapathy, A. S. ; Krishnamoorthy, R. ; Chandy, M. (1999) Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation Bone Marrow Transplantation, 24 (1). pp. 5-11. ISSN 0268-3369
![]()
|
PDF
- Publisher Version
63kB |
Official URL: http://www.nature.com/bmt/journal/v24/n1/abs/17018...
Related URL: http://dx.doi.org/10.1038/sj.bmt.1701814
Abstract
The pharmacokinetics of busulphan were studied in 23 thalassaemic children undergoing BMT. Patients received busulphan at a dose of either 16 mg/kg with cyclophosphamide and ATG (Group A) or 600 mg/m2 (with cyclophosphamide alone) (Group B) in 16 divided doses every 6 h over 4 days. Busulphan levels were analyzed by a modified GC-MS method. The dose of busulphan/kg for patients in group B was 64% (range 56-71%) higher than that for patients in group A. The mean AUC, Css, Cmax and MRV were significantly higher in group B as compared with group A for both doses 1 and 13. There was no significant difference in Vd/F, T1/2 and Kel between the two groups. A significant decrease in AUC and Css was found between 1st and 13th doses in group B, but not in group A. The Cl/F values in group A were significantly higher than those in group B after dose 1, but not after dose 13. No increase in toxicity due to the higher dose of busulphan was noted. We conclude that busulphan at 600 mg/m2 results in much higher systemic exposure to the drug as compared to 16 mg/kg, without increase in toxicity in children with beta thalassaemia major.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Nature Publishing Group. |
Keywords: | Busulphan; Pharmacokinetics; Bone Marrow Transplantation; Thalassaemia |
ID Code: | 5754 |
Deposited On: | 19 Oct 2010 11:08 |
Last Modified: | 16 May 2016 16:12 |
Repository Staff Only: item control page